



LKT Laboratories, Inc.

OSI-906

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID O7333

CAS No. 867160-71-2

Chemical Name

Synonym OSI906, Linsitinib

Formula $C_{26}H_{23}N_5O$

Formula Wt. 421.49

Melting Point

Purity $\geq 98\%$

Solubility DMSO 84 mg/mL (199.29 mM)

Water Insoluble


Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description

OSI-906 inhibits IGF-1R and InsR, displaying anticancer chemotherapeutic activity; it is currently in clinical trials as a potential treatment for colorectal cancer. In animal models of ovarian cancer, OSI-906 inhibits tumor development and growth. This compound also decreases tumor growth in animal models of fibroblast tumors. OSI-906 inhibits cell proliferation in colorectal cancer, breast cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC) cells.



Bulk quantities available upon request

Product ID	Size
O7333	5 mg
O7333	25 mg
O7333	50 mg

References Bendell JC, Jones SF, Hart L, et al. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. *Invest New Drugs*. 2015 Feb;33(1):187-93. PMID: 25335932.

Rao W, Li H, Song F, et al. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells. *Carcinogenesis*. 2014 Jul;35(7):1573-81. PMID: 24667688.

Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. *Future Med Chem*. 2009 Sep;1(6):1153-71. PMID: 21425998.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.